Stock screener

AKBA

Conviction 15HealthcareScan · Thu, Jun 25, 2026
AKBA$1.04-2.36%
ResistanceSupportVol 14
63 bars
Vol MA14 6.97M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Akebia Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.akebia.com
Price1.04
Change-2.36%
Gap+0.47%
Rel volume1.77×
Avg volume6.01M
Avg $ vol5.94M
SMA 200.9876
SMA 501.15
SMA 2001.67
Price vs 50-10.24%
Price vs 200-37.97%
MA stackbearish
50/200 cross
Supertrenddown · 1.11
RSI (14)49
MACD hist0.03
MACD crossbull · 9d
Stoch %K / %D67 / 76
ADX (14)27
+DI / −DI21 / 24
RSI divergenceBullish
MACD divergenceBullish
ATR %+7.01%
ADR %6.98%
52w high4.01
52w low0.8729
From 52w high-74.19%
Above 52w low+18.57%
New 52w highNo
SqueezeOff
Bollinger width26.41%
%B0.68
Donchian pos66.91%
Donchian high1.14
Donchian low0.8227
AVWAP (52w high)1.90
vs AVWAP high-45.53%
AVWAP (52w low)0.9895
vs AVWAP low+4.60%
OBV trendUp
Chaikin MF (20)0.09
Today vs 20d1.77×
Avg vol (14d)6.97M
Avg vol (20d)6.01M
Avg $ vol (20d)5.94M
Market cap277.65M
RS 3m (vs SPY)-34.32%
RS 6m (vs SPY)-43.88%
RS line new highNo
Trend template0/8
Technical rank20.5
1 week+1.47%
1 month-0.48%
3 months-25.54%
6 months-37.65%
1 year-71.80%
YTD-33.23%
P/E-51.95
P/B10.14
P/S1.18
P/FCF4.10
EPS-0.0200
Div yield
ROE-19.53%
ROA-1.47%
Debt/Eq1.79
Current1.40
EV/EBITDA6.52
Gross margin
Net margin-2.26%
Rev growth47.46%
EPS growth92.30%
Price target4.67
Target upside351.21%
Analyst ratingBuy
Institutional44.00%
Ent. value163.89M
Revenue53.54M
Net income-9.05M
Gross profit
Free cash flow67.7M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out268.26M
Employees194
ListedThu, Mar 20, 2014
Free float247.48M
Float %93.3%
Short interest27.42M
Days to cover4.1d
Short volume39.7%
Squeeze score54 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.03 · 2 est
Last EPS vs est−$0.03 vs −$0.01
Last surprise-200.0% miss
Setup gradeD
Conviction15 / 100
Pattern quality
Tech rank20.5 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance1.39
Support0.8488
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in AKBA

All disclosures →
No recent disclosed trades by Congress in AKBA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AKBA · 10 buys

InsiderSideShares
ADAMS ADRIAN
Director · Common Stock · 2026-06-17
Grant35.7K
ADAMS ADRIAN
Director · Stock Option (Right to buy) · 2026-06-17
Grant53.6K
Smith Cynthia
Director · Common Stock · 2026-06-17
Grant35.7K
Smith Cynthia
Director · Stock Option (Right to buy) · 2026-06-17
Grant53.6K
Wolf Myles
Director · Common Stock · 2026-06-17
Grant35.7K
FRIESON RON
Director · Stock Option (Right to buy) · 2026-06-17
Grant53.6K
ZUMWALT LEANNE M
Director · Common Stock · 2026-06-17
Grant35.7K
ZUMWALT LEANNE M
Director · Stock Option (Right to buy) · 2026-06-17
Grant53.6K
ROGERS MICHAEL W
Director · Common Stock · 2026-06-17
Grant35.7K
ROGERS MICHAEL W
Director · Stock Option (Right to buy) · 2026-06-17
Grant53.6K

SEC filings

EDGAR filings in AKBA · 1 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.